KCT0003532招募中未知
Reduction Of Cycles of neOadjuvant Chemotherapy for advanced epithelial Ovarian, fallopian, and primary peritoneal cancer: a phase III randomized controlled trial
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 298
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 18(Year) 至 80(Year)（—）
- 性别
- Female
入选标准
- •(1) Age: 18-80 years old
- •(2) Advanced epithelial ovarian, fallopian or primary peritoneal cancer diagnosed with the following methods
- •? Histologic confirmation by diagnostic laparoscopic or laparotomy
- •? Hisologic malignancy originated from female genital tract on fine needle aspiartion if histological confirmation is difficult or cytologic confirmation of adenocarcinoma in ascites if fine needle aspiration is difficult, meeting the following criteria
- •- Existence of the pelvic or ovarian mass
- •- Identification of tumor >2 cm beyond the pelvis on CT, malignant pleural effusion by thoracentesis, extraperitoneal lymph node metastasis (cardio-phrenic, internal mammary, mediastinal, para-tracheal, supraclavicular lymph nodes or inguinal lymph nodes)
- •- Cancer antigen 125 (CA-125, kU/L)/carcinoembryonic antigen (CEA, ng/ml) >25
- •- if CA-125 (kU/L)/CEA (ng/ml) is 25 or less, no primary lesion on colonoscopy, gastroscopy and mammography within six weeks before randomization.
- •(3) International Federation of Gynecology and Obstetrics(FIGO) stage IIIC to IVB disease
- •(4) World Health Organization(WHO) performance status 0-2
- •(5) The following criteria should be met if synchronous or metachronous tumors excisit.
- •? Complete remission of metachronous malignancy for at least 5 years
- •? Follicular or papillary thyroid cancer treated completely with only surgery as a synchronous tumor
- •? Early gastric or colon cancer treated completely with only endoscopic mucosal resection as a synchrounous tumor
- •(6) Normal hematologic, renal and liver function with the following criteria
- •White blood cell(WBC) =3,000/ul
- •Absolute neutrophil count(ANC) =1,500/ul
- •Platelet =100×103/ul
- •Aspartate aminotransferase(AST) =100 IU/L
- •Alanine aminotransferase(ALT) =100 IU/L
- •Serum total bilirubin =1.5 mg/dL
- •Serum creatinine =1.5 mg/dL
- •(7) Absence of psychological, and socioeconomic limitations affecting participation to this trial
- •(8) Informed consent
排除标准
- •(1) Diagnosis of metachronous malignancy within five years before enrollment
- •(2) Synchronous tumors except follicular or papillary thyroid cancer treated completely with only surgery and early gastric or colon cancer treated completely with only endoscopic mucosal resection
- •(3) Carcinoma in situ, non-epithelial, or borderline tumor in ovary, fallopian tube, and peritoneum
- •(4) Pregnancy
- •(5) Medical conditions (hypertension, diabetes mellitus, infectious or cardiac disease etc.) influencing on survival
- •(6) Clinical evidence of brain or leptomeningeal metastasis, bone metastasis
- •(7) Other treatments affecting clinical outcomes during participation to this trial (hyperthermic intraperitoneal chemotherapy, oncothermia, herbal medicine, etc.)
- •(8) No informed consent
研究者
相似试验
进行中（未招募）
1 期
Reduction in the number of chemotherapy cycles in combination with Pembrolizumab in first-line treatment of PD-L1-positive recurrent or metastatic head and neck squamous cell carcinomasFirst-line treatment of PD-L1-positive recurrent or metastatic head and neck squamous cell carcinomasMedDRA version: 27.0Level: LLTClassification code: 10090001Term: Squamous cell carcinoma of head and neck recurrent Class: 100000004864MedDRA version: 27.0Level: LLTClassification code: 10082179Term: Squamous cell carcinoma of head and neck metastatic Class: 10029104CTIS2024-514875-16-00Oncopole Claudius Regaud93
已完成
不适用
Prospective study of neoadjuvant chemotherapy for HER2 positive breast cancer.JPRN-UMIN000046338Sapporo Medical University24
尚未招募
不适用
A study comprising of chemotherapy and radiotherapy before the surgery of locally advanced rectal cancer.CTRI/2019/08/020847AIIMS New Delhi
已完成
不适用
A Prospective Study of Neoadjuvant Chemotherapy with Nivolumab/Gemcitabine/Cisplatin in Muscle-Invasive or Locally-Advanced Urothelial Carcinoma of BladderKCT0003804Samsung Medical Center48
招募中
不适用
Prospective study of neoadjuvant chemotherapy with FEC100x4 for BRCAness cases in triple negative breast cancerBreast cancerJPRN-UMIN000029433Tokyo medical university70